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Background: We evaluated whether obstructive sleep apnoea (OSA) and continuous positive
airway pressure (CPAP) treatment influence left ventricular (LV) remodelling independently
of abdominal obesity and metabolic syndrome (MetS).
Methods: Cardiorespiratory examination, 24-h BP monitoring and echocardiogram were per-
formed in overweight/obese patients with increased abdominal adiposity and symptoms sug-
gesting OSA : OSA/MetS (n.50), OSA/noMetS (n.22), noOSA/MetS (n.29), noOSA/noMets
(n.16). The evaluation was repeated in 41 patients after 18 months of CPAP.
Results: Despite similar age, gender, BMI and 24-h BP, the 2 groups with MetS had greater LV
remodelling (LV hypertrophy and diastolic dysfunction) than the 2 groups without MetS. From
multiple regression analysis independent determinants for LV mass were MetS, 24-h systolic BP
and age, for LV diastolic function were LV mass index, MetS and age. After CPAP, the 20
patients with decreased body weight showed diastolic BP decrease, LV hypertrophy regression
and diastolic function improvement, whereas, despite similar respiratory improvement, BP and
LV parameters were unchanged in the 21 patients with body weight unchanged/increased.of Clinical Medicine, University of Insubria, Viale Borri 57, Varese, Italy. Tel.: þ39 332 278403; fax:
t (A.M. Grandi).
1 Elsevier Ltd. All rights reserved.
146 A.M. Grandi et al.Conclusion: In patients with increased abdominal adiposity, LV remodelling is not associated to
OSA per se; chronic CPAP treatment does not influence LV remodelling whose regression is
mainly linked to body weight decrease.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Obstructive sleep apnoea (OSA) is associated with increased
cardiovascular morbidity and mortality.1 This high cardio-
vascular risk is accounted for by factors linked to OSA per se,
including its mechanical, neurohumoral, inflammatory and
oxidative effects, and by cardiovascular risk factors, such as
male gender and visceral obesity, that are also risk factors for
OSA, making it difficult to distinguish the possible indepen-
dent role ofOSA.1 A relevant role in increasing cardiovascular
risk is probably played by the development of left ventricular
(LV) remodelling: in fact OSA has been associated to LV
morpho-functional changes, mainly characterized by
myocardial hypertrophy and diastolic dysfunction, both
known independent cardiovascular risk factors.2,3 Actually
the studies about LV remodelling in OSA reached partly
different conclusions about characteristics and extent of LV
changes and also about the possible direct role of OSA as
a cause of LV remodelling.4e8 As well, few data are available
about the effects of continuous positive airway pressure
(CPAP), the standard therapy for OSA,9 on LV characteristics:
a 6-month treatment with CPAP appears to induce at least
some degree of regression ofmyocardial hypertrophy and/or
diastolic dysfunction.6,7,10,11
The different conclusions reached by studies on LV
remodelling in OSA might be accounted for by differences
with regard to methods employed, LV parameters evalu-
ated and patients characteristics, such as body weight and
blood pressure (BP). In fact, visceral obesity and arterial
hypertension are highly prevalent in OSA and both are
linked per se to the development of LV hypertrophy and
diastolic dysfunction.12 Moreover, all the studies about LV
morphology and function in OSA did not investigate the
presence of metabolic syndrome (MetS). This cluster of
cardiovascular risk factors, including visceral obesity, high
BP, fasting hyperglycaemia and atherosclerotic dyslipide-
mia,13 has been linked per se to the development of LV
remodelling in the general population and in hypertensive
subjects.14,15 MetS prevalence seems to be high in OSA,
either due to the concomitant abdominal obesity or to
a direct link between OSA and MetS.16e18
Moving from these considerations, we evaluated, in
subjects with increased visceral adiposity, whether OSA and
CPAP treatment influence LV remodelling independently of
coexisting abdominal obesity and MetS. To this goal we
designed a study divided into 2 parts : 1) a cross-sectional
part aimed to examine the association between OSA, MetS
and LV characteristics, 2) a longitudinal part aimed to
evaluate the effects of chronic (18 months) CPAP treat-
ment on LV morphology and function, taking also into
account the concomitant changes in body weight, because
of the known influence of weight changes on LV morpho-
functional characteristics in obesity.19Methods
Patients and design
Cross-sectional study
Among the subjects referred to the respiratory out-
patients’ clinics of Cuasso al Monte and Somma Lombardo
Hospitals for symptoms suggesting possible OSA (i.e.
daytime hypersomnolence and/or snoring) we consecu-
tively enrolled patients with the following characteristics:
BMI >25 kg/m2 and waist circumference >88 cm in
women, >102 cm in men, LV echocardiogram of good
quality and repeatable, no previous or current treatment
with statins, beta-blockers or diuretics, no diabetes mel-
litus, COPD or thyroid disorders, no clinical, electrocar-
diographic or echocardiographic signs of heart failure,
coronary artery disease or valvular heart diseases, no
history of cerebrovascular or peripheral artery disease. We
also excluded the patients with upper airway resistance
syndrome or central sleep apnoea (Recruitment Flow-
chart, as Figure S1, online supplement file).
Following thesecriteria,weenrolled117patients (89men,
28 women, mean age 55 10 years, mean BMI 31.8 4.6 kg/
m2, mean waist circumference 110.3  7.4 cm).
Each patient underwent: daytime sleepiness evaluation
with Epworth Sleepiness Scale score,20 night-time cardio-
respiratory examination, 24-h ambulatory BP monitoring,
LV echocardiogram, blood tests for the evaluation of
metabolic profile.
Longitudinal study
All the patients with OSA underwent counselling about
lifestyle corrections (dietary changes and regular physical
activity aimed to lose weight). The recommended lifestyle
changes and the adherence to them were discussed at any
following visit. All the 56 patients with apnoea/hypopnoea
index (AHI)  15 events/hour began CPAP treatment and
underwent a visit at the respiratory clinic after 6 months
and then once a year.
After at least 18 months of CPAP treatment, a second
evaluation (Epworth sleepiness scale, night-time cardio-
respiratory examination, 24-h ambulatory BP monitoring,
LV echocardiogram and blood tests) was performed in 41
patients who have not changed the basal drug treatment
and used CPAP  4 h per night. The other 15 patients
treated with CPAP were excluded from the second evalua-
tion because of anti-hypertensive treatment changes (7
patients) and/or CPAP use < 4 h per night (10 patients).
The study was approved by the Ethical Committee of the
Ospedale di Circolo and all the patients gave their informed
consent.
See online supplementary file for: MetS diagnosis, HOMA
index evaluation, night-time cardio-respiratory examination,
Figure 1 Prevalence of metabolic syndrome in patients with
mild, moderate, severe OSA and without OSA (OSA-).
OSA, metabolic syndrome and CPAP 147diagnosis of OSA, CPAP ventilation, 24 h ambulatory BP
monitoring, echocardiographic examination.
Statistical analysis
The statistical analysis was performed using the SPSS 11.5
software; data are expressed as mean values (SD) or
percentage; a probability value <0.05 (two-sided) was
considered statistically significant.
Cross-sectional study
The patients were divided according to the pre-
sence/absence of OSA and MetS : OSA/MetS, OSA/noMetS,
noOSA/MetS, noOSA/noMetS. We compared mean values of
all the parameters among the 4 groups by means of 2
(between OSA and no OSA) by 2 (between MetS and no
MetS) ANOVA, followed by the test of Scheffe´. We also
compared mean values of all the parameters among
patients with mild (AHI 5e14 events/hour), moderate (AHI
15e29 events/hour) and severe OSA (AHI  30 even-
ts/hour), using one-way analysis of variance (ANOVA) and
Scheffe´ test. This latter was chosen since it is known to be
conservative and reliable in post-hoc analysis between
three or more groups.21 Chi-square test was used to
compare proportions. Multiple regression analyses were
performed to identify independent predictors of LV mass
and diastolic function by a stepwise procedure with,
respectively, LV mass index and Em/Am ratio as dependent
variables. The independent variables were age, gender,
BMI, 24-h systolic and diastolic BP, 24-h heart rate, AHI,
oxygen desaturation index (ODI), Epworth Sleepiness score
and MetS (as a dummy variable by assigning 1 to MetS and 2
to noMetS); LV mass index was added as independent
variable in the analysis for Em/Am ratio. Both regression
analyses were repeated removing MetS and adding its
individual components, with the exclusion of waist
circumference because of its high correlation with BMI.
Longitudinal study
By means of paired Student’s t test we evaluated the
changes of respiratory, BP, metabolic and LV parameters
from basal to second evaluation in 41 patients treated with
CPAP.
Then the patients were divided on the basis of weight
changes from baseline : patients with weight decreased
(2 kg) and patients with weight unchanged or increased
(2 kg). We used 2 (between decreased weight and
unchanged/increased weight group) by 2 (repeated
measures with 2 levels : basal and second evaluation)
ANOVA, followed by the test of Scheffe´, in order 1) to
compare basal values between the 2 groups, 2) to evaluate
longitudinal changes within each group, 3) to compare the
effects of weight changes (decrease vs no change/increase)
on respiratory, BP, metabolic and LV parameters.
Results
Cross-sectional study
OSA was diagnosed in 72 patients : 16 mild OSA (AHI 5-14
events/hour), 18 moderate OSA (AHI 15-29 events/hour)and 38 severe OSA (AHI  30 events/hour). MetS was found
in 79 patients and its prevalence was similar among
subjects with mild, moderate, severe OSA and without OSA
(Figure 1).
We divided the patients according to the pre-
sence/absence of OSA and MetS : OSA/MetS (50 patients),
OSA/noMetS (22 patients), noOSA/MetS (29 patients),
noOSA/noMetS (16 patients). The 4 groups were not
significantly different with regard to age, gender, BMI,
waist circumference, heart rate and BP throughout the 24 h
(Table 1 and Table S1, see online supplement file). The
prevalence of hypertension (24-h BP > 125 and/or
80 mmHg)22 and of chronic anti-hypertensive treatment
(with ACE inhibitors, Angiotensin II receptors blockers
and/or calcium-antagonists) were also similar among the 4
groups (Table 1). AHI, ODI and Epworth Sleepiness score
were higher and mean nocturnal O2 saturation lower in the
2 groups with OSA (Table 1), whereas triglycerides, fasting
glucose and HOMA index were higher and HDL cholesterol
lower in the 2 groups with MetS (Table S1, see online
supplement file).
With regard to LV characteristics (Table 1), LV end-
diastolic diameter and LV ejection fraction were normal
in all the subjects (<57 mm, 55%)22 and similar among the
4 groups. Compared to the 2 groups without MetS, the 2
groups with MetS had higher septal and posterior wall
thickness, relative wall thickness and LV mass index, lower
LV diastolic indices (Em/Am and E0/A0) and greater preva-
lence of LV hypertrophy (LV mass > 44 g/m2.7 in women,
>48 g/m2.7 in men)23 and diastolic dysfunction (at least 2 of
the followings : E/A < 1, E0/A0 < 1, Em/Am < 1). No
differences in LV morpho-functional parameters were
found between the 2 groups with MetS (OSA/MetS and
noOSA/MetS), as well as between the 2 groups without MetS
(OSA/noMetS and noOSA/noMetS). ANOVA (2  2 factors)
showed a significant effect of MetS on metabolic parame-
ters, septal and posterior wall thickness, LV mass index and
diastolic parameters, with a significant effect of OSA on
respiratory parameters only.
Mean values of LV morpho-functional parameters were
not significantly different comparing patients with mild,
moderate and severe OSA (data not shown).
From stepwise multiple regression analyses (Table S2),
themain independentpredictors of LVmass indexwereMetS,
24-h systolic BP and age; after removing MetS from the
equation, the main independent determinants were 24-h
systolic BP, BMI and age. The main independent predictors
Table 1 Mean values (SD) of anthropometric, respiratory and LV parameters in patients subdivided on the basis of presence/
absence of OSA (OSA, noOSA) and MetS (MetS, noMetS).
Anthropometric parameters OSA noOSA ANOVA
MetS (n Z 50) noMetS (n Z 22) MetS (n Z 29) noMetS (n Z 16) OSA MetS
Age, years 55  10 54  12 56  9 56  11 ns ns
Men/women 40/10 17/5 20/9 12/4 ns ns
Body mass index, kg/m2 32.4  4.6 31.9  6.1 31.3  3.8 31.8  4.6 ns ns
Waist circumference, cm 111.7  8.2 110.5  7.4 108.4  7.6 110.2  6.9 ns ns
Respiratory parameters
AHI, events per hour 39.3  24a 37.8  21a 2.6  1.4 2.7  1.5 <0.001 ns
ODI, events per hour 38.3  25.7a 41.5  27.8a 4.1  6.1 4.3  3.9 <0.001 ns
Mean nocturnal SaO2, % 91.2  5.1a 90.9  4.6a 95.8  1.8 95.5  1.6 <0.001 ns
Epworth Sleepiness score 10.4  5.7a 10.7  4.6a 5.2  3.4 5.3  3.7 <0.001 ns
LV parameters
LV diastolic diameter, mm 48.7  6.5 49.3  4.8 48.6  6.7 48.9  4.6 ns ns
Septal thickness, mm 11.3  1.7b 9.7  1.5 11.5  1.5b 9.8  1.2 ns <0.001
Wall thickness, mm 11.1  1.4b 9.5  1.5 10.9  1.6b 9.5  1.2 ns <0.001
Relative wall thickness 0.46  0.07b 0.39  0.05 0.46  0.08b 0.39  0.06 ns <0.001
LV mass index, g/m2.7 58.6  17.6b 45.2  12.6 59.5  18.8b 47.4  13.4 ns <0.001
Ejection fraction,% 64  5 62  4 63  7 64  6 ns ns
E/A 0.94  0.24 0.96  0.22 0.98  0.32 0.97  0.26 ns ns
Em/Am 0.84  0.27b 1.08  0.31 0.87  0.29b 1.02  0.33 ns 0.005
E0/A0 0.76  0.25b 0.95  0.27 0.73  0.30b 0.97  0.24 ns 0.002
LV hypertrophy, n. (%) 42 (84%)b 9 (41%) 24 (82.7%)b 7 (43.7%) ns <0.001
Diastolic dysfunction, n.(%) 30 (60%)b 4 (18.2%) 19 (65.5%)b 3 (18.7%) ns <0.001
AHI: apnoea/hypopnoea index; ODI : oxigen desaturation index; SaO2 : arterial oxigen saturation; LV: left ventricular; E/A : ratio
between peak early (E) and peak late transmitral flow velocity (A); Em/Am: ratio between peak early (Em) and peak late (Am) diastolic
velocity of myocardial lateral wall; E0A0 : ratio between peak early (E0) and peak late (A0) diastolic velocity of interventricular septum.
a P < 0.001 OSA vs no OSA.
b 0.02 < P < 0.001 MetS vs noMetS.
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index, MetS and age; after removing MetS, BMI entered the
equation. AHI, ODI, Epworth Sleepiness score and the single
components of MetS did not enter the equations.Longitudinal study
Mean length of CPAP treatment was 23.9 4.8 months. After
CPAP treatment the 41 patients showed the following
significant changes: decrease of weight, BMI and waist
circumference, improvement of all respiratory parameters,
reduction of 24-h, daytime and night-time diastolic BP and
heart rate, decrease of triglycerides, fasting glycaemia and
HOMA index, decrease of relative wall thickness and LV mass
index, due to significant reduction of septal and posterior
wall thickness, with improvement of LV diastolic parameters
(E/A and Em/Am)(Table S3, see online supplement file).
Looking at weight changes during treatment we found
that from basal to second evaluation body weight decreased
2 kg in 20 patients (Yweight group, from 100.3  17 kg to
93.6  15.4 kg, P < 0.0001), whereas in 21 patients body
weight was unchanged (12 patients) or increased  2 kg (9
patients) (Z/[weight group, from 91.8  13.2 kg to
93.9  13.9 kg, p Z 0.015). At baseline the 2
groups were similar with regard to age (Yweight 55  10
years vsZ /[weight 53  9 years, ns), gender (men/women
Yweight 15/5 vs Z /[weight 18/3, ns), heart rate and BP
throughout the 24 h, metabolic parameters and LV systolicand diastolic indices (Tables 2 and 3); Yweight group had
lower height (1.68  0.09 m vs 1.74  0.08 m, p Z 0.03),
higher BMI, waist circumference and LV mass index (Tables 2
and 3). Length of CPAP treatment (Yweight 23.2  4.3
months vs Z /[weight 24.5  5.2 months, ns)
and average nightly use of CPAP (Yweight 5.5  1.2 h/night
vsZ /[weight 5.7 1 h/night, ns) were similar between the
2 groups. After treatment all respiratory parameters
improved significantly in both groups (Table 2); the extent of
improvement was similar between the 2 groups: AHIYweight
89.3  15.5% vs Z /[weight 88.6  16.8%, ns; ODI
Yweight 93.4  7.6% vsZ /[weight 92.6  10.2%, ns.
The Yweight group showed the following significant
changes: decrease of BMI, waist circumference, diastolic BP
and heart rate throughout the 24 h, triglycerides, fasting
glucose, HOMA index, relative wall thickness, LV mass index
(due to reduction of septal and posterior wall thickness),
improvement of LV diastolic indices (Tables 2 and 3). In the
group with Z /[weight metabolic, BP and LV parameters
remained unchanged (Tables 2 and 3). ANOVA (2x2 factors)
showeda significanteffectofweight changeonBP,heart rate,
metabolic andLVparameters,witha significanteffectofCPAP
treatment only on respiratory parameters (Tables 2 and 3).Discussion
As far as we know this is the first study that evaluated: 1) LV
remodelling in OSA taking into account the presence of
Table 2 Mean (SD) values of anthropometric, respiratory and BP parameters before and after CPAP in patients with
decreased weight (Yweight) and in patients with unchanged/increased weight (Z/[weight).
Anthropometric parameters Y weight (n Z 20) Z/[ weight (n Z 21) ANOVA
basal CPAP basal CPAP CPAP Weight change
Body mass index, kg/m2 35.1  4.6b 32.9  4.5c 30.8  4.1 31.1  4.3c ns 0.002
Waist circumference, cm 115.8  8.9a 110.7  9.9c 107.3  10.2 107.9  11.1 ns 0.011
Respiratory parameters
AHI, events per hour 45.6  20.3 4.7  6.1c 45.3  22.3 5.3  6.5c <0.001 ns
ODI, events per hour 45  19.5 2.9  3.1c 44.4  20.8 3.4  4.2c <0.001 ns
Mean nocturnal SaO2,% 89.9  6.6 95.5  1.3c 90.5  5.3 95.7  1.6c <0.001 ns
Epworth sleepiness scale 12.4  4.4 6.5  3.9c 11.3  4.8 4.5  3.3c <0.001 ns
BP and HR parameters
Systolic BP 24h, mmHg 128  10 125  11 126  12 125  13 ns ns
Diastolic BP 24h, mmHg 78  10 72  9c 77  9 76  11 ns 0.016
Heart rate 24h, bpm 73  9 67  8c 73  10 72  11 ns 0.021
Systolic BP day, mmHg 131  10 129  12 129  11 127  14 ns ns
Diastolic BP day, mmHg 82  10 76  11c 81  9 80  12 ns 0.019
Heart rate day, bpm 76  9 72  9c 78  10 76  12 ns 0.015
Systolic BP night, mmHg 121  12 116  13 117  11 117  14 ns ns
Diastolic BP night, mmHg 71  10 65  8c 71  10 70  11 ns 0.013
Heart rate night, bpm 69  9 60  8c 65  9 64  10 ns 0.019
a P Z 0.007.
b P Z 0.003 basal Yweight vs basal Z /[weight.
c 0.02 < P < 0.001 CPAP vs basal, see Table 1
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LV remodelling, taking into account the concomitant
changes of body weight.
From our results, in patients with increased abdominal
adiposity and without known cardiovascular diseases : 1) LV
remodelling seems to be associated to MetS and abdominal
obesity, not to OSA per se, 2) chronic CPAP treatment does
not significantly influence LV remodelling, whose regression
is mainly linked to body weight decrease.
Designing this study we used restrictive enrolment
criteria. First, because OSA and MetS are far more frequent
in subjects with increased visceral adiposity and this latter
is also linked per se to LV remodelling,24,25 we decided to
enrol only overweight or obese subjects (BMI > 25 kg/m2)
with increased abdominal adiposity (waist
circumference > 102 cm in men, >88 cm in women) in
order to avoid the confounding effect that comes from
mixing patients with and without abdominal obesity. We did
not limit the enrolment to patients with BMI 30 kg/m2
because increasing evidence suggests that, also in the
absence of clear-cut obesity, increased abdominal fat,
expressed by increased waist circumference, is associated
with a higher incidence of OSA and metabolic abnormali-
ties.26 Patients previously or currently treated with beta-
blockers and/or diuretics were excluded because these
drugs can have detrimental metabolic effects, increasing
per se MetS incidence.27 We also excluded patients treated
with statins that, beside lipid levels, seem able to influence
BP values and possibly LV characteristics.28 For the longi-
tudinal study we employed another important criterion:
only the patients who had not changed their drug treatment
from baseline underwent the second evaluation, in order to
avoid the confounding effect of new drug treatments on LV
characteristics. These selection criteria greatly reducedthe number of eligible patients for the cross-sectional as
well as the longitudinal study, but allowed us to avoid some
relevant confounding factors.
We evaluated LV remodelling by means of echocardiog-
raphy, whose reliability in assessing left ventricular
morpho-functional characteristics is supported by a very
large body of data obtained from cross-sectional and
longitudinal studies on healthy subjects and patients with
many different pathologies.
High BP is a key component of MetS and influences per se
LV remodelling, making a reliable assessment of BP profile
very important for our purpose. Therefore, at odds with
most previous studies on LV characteristics in OSA, we did
not rely on clinic BP measurements, but we used 24-h
ambulatory BP monitoring, more reliable in defining the
actual BP burden and more correlated with target organ
damage than clinic BP values.29
In our subjects MetS prevalence was not different among
patients with mild, moderate, severe OSA and without OSA
(Figure 1). This result, in agreement with some, but not all
the previous studies,16e18 indicates that the presence of
MetS is not linked to OSA per se, at least in overweight/
obese subjects with increased visceral adiposity.
With regard to LV remodelling, the 2 groups with MetS
(OSA/MetS and noOSA/MetS) had higher LV mass index (due
to greater wall thickness), lower mean values of diastolic
indices and higher prevalence of LV hypertrophy and dia-
stolic dysfunction than the 2 groups without MetS (OSA/no
MetS and noOSA/noMetS). The presence of OSA was not
associated to LV remodelling, whose main independent
determinants were for LV mass MetS, 24-h systolic BP and
age, for LV diastolic function LV mass, MetS and age, as
shown by the results of multiple regression analyses. These
analyses also confirmed the well known role of obesity as
Table 3 Mean values(SD) of metabolic and LV parameters before and after CPAP treatment in patients with decreased
weight (Yweight) and in patients with unchanged/increased weight (Z/[weight).
Metabolic parameters Y weight (n.20) Z/[ weight (n.21) ANOVA
Basal CPAP Basal CPAP CPAP Weight change
Total Cholesterol, mg/dL 228  46 217  53 218  39 213  29 ns ns
HDL Cholesterol, mg/dL 45  10 48  11 46  10 48  12 ns ns
LDL Cholesterol, mg/dL 149  38 142  43 135  34 141  30 ns ns
Triglycerides, mg/dL 165  56 131  57b 167  72 163  62 ns 0.016
Fasting glucose, mg/dL 100  10 94  8b 100  11 102  13 ns 0.010
HOMA index 3.5  1.4 2.4  1.5b 3.4  1.7 3.6  2.1 ns 0.014
LV parameters
LV diastolic diameter, mm 50  5 50  6 49  5 49  4 ns ns
Septal thickness, mm 11.6  1.2 10.5  0.9b 11.5  1.4 11.6  1.5 ns 0.006
Posterior wall thickness, mm 11.4  1.3 10.4  1.1b 11.1  1.2 11  1.3 ns 0.008
Relative wall thickness 0.46  0.06 0.42  0.05b 0.46  0.08 0.46  0.07 ns 0.003
LV mass index, g/m2.7 64.7  13.2a 55.3  11.4b 54.9  12.7 56.1  12.4 ns 0.008
LV Ejection fraction, % 63  4 64  5 64  4 65  4 ns ns
E/A 0.91  0.24 1.07  0.29b 0.95  0.21 0.97  0.28 ns 0.018
Em/Am 0.82  0.23 0.98  0.27b 0.93  0.28 0.91  0.25 ns 0.016
E0/A0 0.74  0.26 0.79  0.18 0.75  0.26 0.76  0.22 ns ns
a P < 0.05 basal Yweight vs basal Z /[ weight.
b 0.05 < P < 0.001 CPAP vs basal see Table 2.
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that BMI entered both the equations after removing MetS.
Respiratory parameters did not enter the equations,
meaning that they were not independent predictors of LV
remodelling. We have to underline that the 4 groups were
similar with regard to age, gender, BMI, waist circumfer-
ence, and BP throughout the 24 h, all factors able to
influence LV mass and diastolic function. Moreover the
prevalence of arterial hypertension and the number of
patients on chronic anti-hypertensive treatment were also
similar among the 4 groups.
Besides high BP and increased visceral adiposity, other
MetS components can influence the development of detri-
mental LV remodelling, including hyperinsulinemia and
sympathetic activation, both able to stimulate myocardial
cells hypertrophy and connective tissue growth.
Our results are at odds with previous studies that found
greater LV mass and/or diastolic impairment in OSA
patients compared to subjects without OSA.5e7 However, in
some of these studies OSA patients were older, more obese
and/or with higher clinic BP than controls and, moreover,
MetS presence was never evaluated.
We can not exclude that in other settings OSA could
influence per se LV remodelling, but from our results MetS
and abdominal obesity outweigh OSA effects on LV
characteristics.
With regard to the longitudinal study, after the basal
evaluation we gave advice about diet and physical activity
to all the patients in order to obtain weight decrease, but,
as it usually happens in clinical practice, the adherence to
the advice was very different, with some patients losing
weight, others maintaining the same weight or increasing
it. Considering together the 41 patients who underwent the
evaluation after CPAP, we could conclude, partly in
agreement with some previous studies,6,7,10,11,29 that CPAP
has a positive effect on LV remodelling, inducing regressionof LV hypertrophy with a modest, but statistically signifi-
cant improvement of diastolic function, together with
a decrease of diastolic BP and heart rate throughout the
24 h and an improvement of metabolic profile. However,
when we divided the patients on the basis of weight
changes, we found that only the patients who lose weight
during CPAP treatment showed regression of LV hyper-
trophy and improvement of LV diastolic, together with
decrease of 24-h diastolic BP and heart rate and improve-
ment of metabolic profile, characterized by lower triglyc-
erides and improved insulin sensitivity. The group of
patients with unchanged/increased weight did not show
any change in LV characteristics, BP values and metabolic
parameters. We have to underline that at baseline all the
respiratory, metabolic, BP and LV parameters were similar
between the 2 groups, with the exception of BMI, waist
circumference and LV mass index, higher in the group that
lose weight during treatment. Moreover length of CPAP
treatment, average nightly use of CPAP and extent of
respiratory improvement were similar in the 2 groups. Our
results are in agreement with literature data about
improvement of LV characteristics after weight reduction in
obese people.19 At odds with previous studies,6,7,10,11,30e32
in our patients CPAP treatment, beside its efficacy in
improving respiratory function, seems not to exert any
relevant and independent effect on LV remodelling, as well
as on BP and metabolic parameters. However, our study is
difficult to compare with previous ones because of some
relevant differences, such as longer CPAP treatment (18
months), lack of changes in drug therapy during CPAP and
evaluation of concomitant body weight changes.
The main limitation of our study is the relatively small
number of subjects examined, due to the strict
enrolment criteria employed. As a consequence some
groups in the cross-sectional study and the groups evalu-
ated in the longitudinal study were rather small, reducing
OSA, metabolic syndrome and CPAP 151the possibility to control for significant confounders. On the
other hand, the small number of patients makes more
relevant the finding of statistically significant differences
among the groups.
Conclusion
From our results, in overweight/obese patients LV remod-
elling is associated to MetS and abdominal obesity, not to
OSA per se, and, probably more important, the regression
of LV remodelling during CPAP treatment is driven by
weight decrease, not by CPAP treatment in itself. Our
findings, that need to be confirmed in larger studies, indi-
cate that in obese patients with OSA we can not rely on
CPAP treatment and consequent respiratory improvement
in order to obtain regression of LV remodelling, but we have
to strongly focus on dietary and lifestyle interventions in
order to obtain weight decrease as the main way to improve
LV characteristics.
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